Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience

Muscle and Nerve

Volumn 41, Issue 3, 2010, Pages 370-374

  Pasnoor, Mamatha ^a   Wolfe, Gil I ^b   Nations, Sharon ^b   Trivedi, Jaya ^b   Barohn, Richard J ^a   Herbelin, Laura ^a   McVey, April ^a   Dimachkie, Mazen ^a   Kissel, John ^c   Walsh, Ronan ^d   Amato, Anthony ^d   Mozaffar, Tahseen ^e   Hungs, Marcel ^e   Chui, Luis ^e   Goldstein, Jonathan ^f   Novella, Steven ^f   Burns, Ted ^g   Phillips, Lawrence ^g   Claussen, Gwendolyn ^h   Young, Angela ^h   Bertorini, Tulio ⁱ   Shin, O H ^h   more..

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acetylcholine receptor antibody; MuSK; Myasthenia gravis

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MUSCLE ANTIBODY; MUSCLE SPECIFIC KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BULBAR PARALYSIS; CAUCASIAN; CHILD; CONTROLLED STUDY; DISEASE DURATION; DYSPNEA; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE ATROPHY; MYASTHENIA GRAVIS; ONSET AGE; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; CHILD; DISEASE-FREE SURVIVAL; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MEDICAL RECORDS; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PREDNISONE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THYMECTOMY; TREATMENT OUTCOME; UNITED STATES;

EID: 77649169688     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21533     Document Type: Article

References (28)

1. Hoch W,McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
2. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006;116:1016-1024.
3. Selcen D, Fukuda T, Shen XM, Engel G. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62: 1945-1950.
4. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57: 289-293.
5. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006;175:107-117.
6. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008;63:782-789.
7. Herbst R, Burden SJ. The juxtamembrane region of MuSK has a critical role in agrin mediated signaling. EMBO J 2000;19:67-77.
8. Wolfe GI, Trivedi JR, Oh SJ. Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis. J Clin Neuromusc Dis 2007;8:217-224.
9. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60:1978-1980.
10. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004;30:55-60
11. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55:16-23.
12. Hatanaka Y, Hemmi S, Morgan MB, Scheufele ML, Claussen GC, Wolfe GI, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005;65: 1508-1509.
13. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, et al. Racial differences in myasthenia gravis in Alabama. Muscle Nerve 2009;39:328-332.
14. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007;68: 609-611.
15. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
16. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129:1481-1492.
17. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099-1102.
18. Lee JY, Sung JJ, Cho JY, Oh DH, Kim HJ, Park JH, et al. MuSK anti-body-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci 2006;13:353-355.
19. Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, Hattori T, Takamori M, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 2005;76:714-718
20. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005;116:2065-2068.
21. Behin A, Mayer M, Kassis-Makhoul B, Jugie M, Espil-Taris C, Ferr X, et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromusc Disord 2008;18:443-446.
22. Niks EH, Verrips A, Semmekrot BA, Prick MJJ, Vincent A, van Tol MJD, et al. A transient neonatal myasthenic syndrome with anti-MuSK antibodies. Neurology 2008;70:1215-1216.
23. Oh SJ, Hatanaka Y, Hemmi S, Young AM, Scheufele ML, Nations SP, et al. Repetitive nerve stimulation of facial muscles in musk antibody-positive myasthenia gravis. Muscle Nerve 2006;33:500-504.
24. FarrugiaME, Kennett RP,Newsom-Davis J,Hilton-JonesD, Vincent A. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006;33:568-570.
25. Oh SJ. Electromyography: neuromuscular transmission disorder. Baltimore: Williams & Wilkins; 1988.
26. Evoli A, Bianchi R, Riso R, Minicugi GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008;1132:76-83
27. Sanders D, Massey J, Juel V. MuSK antibody positive myasthenia gravis: response to treatment in 31 patients [abstract]. Neurology 2007:68:A299.
28. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-448.